Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.1K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

398
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
398
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

383
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
383
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidimensional Longitudinal Assessment of Oral Mucositis Burden and Functional Impact in Head and Neck Cancer Patients Undergoing Radiotherapy or Chemoradiotherapy: A Retrospective and Exploratory Observational Study.

Cancers·2026
Same author

Exploratory Analysis of the Neutrophil-to-Lymphocyte Ratio (NLR) and Mucositis Severity in Head and Neck Cancer Patients Undergoing Radiotherapy-Based Treatment: A Retrospective Study.

Journal of clinical medicine·2026
Same author

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.

Melanoma research·2025
Same author

Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.

Journal of advanced research·2025
Same author

Novel De Novo <i>BRCA2</i> Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

International journal of molecular sciences·2025
Same author

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

British journal of haematology·2024

Related Experiment Video

Updated: Apr 18, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Multiple myeloma: is a shift toward continuous therapy needed to move forward?

Tommasina Guglielmelli1, Antonio Palumbo

  • 1Unit of Hematology, 'S. Luigi Gonzaga' Hospital, Orbassano, Italy.

Expert Review of Hematology
|January 14, 2015
PubMed
Summary

Multiple myeloma (MM) treatments have improved, but relapse remains common. Continuous therapy may prolong progression-free survival and keep patients symptom-free.

Keywords:
bortezomibcontinuous therapylenalidomidemaintenancemultiple myelomathalidomide

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Related Experiment Videos

Last Updated: Apr 18, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma (MM) is a significant hematologic malignancy.
  • Current standards of care for newly diagnosed MM patients vary by age and transplant eligibility.
  • Novel agents have expanded treatment options but relapse is frequent.

Discussion:

  • Despite advances, most MM patients relapse after initial therapy.
  • There is an urgent need for novel drugs and treatment strategies.
  • Continuous therapy is a potential strategy to manage MM.

Key Insights:

  • Melphalan-based regimens are standard for transplant-ineligible patients.
  • Novel agent induction followed by transplantation is standard for eligible patients.
  • Relapse after first-line therapy is a major challenge in MM management.

Outlook:

  • Further research into novel therapeutic agents is crucial.
  • Continuous therapy may offer a way to prolong remission and survival.
  • Improving long-term outcomes for MM patients remains a key goal.